-Initial dose: 50 mg orally once a day during the menstrual cycle
-Maintenance dose: 50 to 150 mg orally once a day during the menstrual cycle
-Initial dose: 50 mg orally once a day starting 14 days prior to the anticipated start of menstruation through to the first full day of menses, and repeated with each new cycle
-Maintenance dose: 50 to 100 mg orally once a day
-The dose may be increased in increments of 50 mg per menstrual cycle, increased at the onset of each new cycle; dosage adjustments may also include changes between regimens.
-If a 100 mg once daily dose has been established with the cyclic regimen, a titration step of 50 mg per day for three days should be used at the beginning of each dosing period (luteal phase of the menstrual cycle).
-The effectiveness of sertraline for longer than three months has not been systematically evaluated in controlled trials.
Treatment of premenstrual dysphoric disorder (PMDD)
Intraocular pressure, glaucoma
Have you heard of DHEA causing high IOP (intraocular pressure) or possibly temporary glaucoma. I have been taking DHEA for about a year. I like the benefits it has provided both physically and mentally. However my last flight physical for the military showed me having high IOP in both eyes. Two days after I stopped taking DHEA my pressures where back to normal.
I have not heard of this side effect yet, and I have not seen it mentioned in the medical literature, however it is a possibility to consider. There's a lot we don't know about the long term effects of DHEA. If your IOP is increased again after restarting the DHEA and then returns to normal after stopping, then that would make it quite likely that in your case it was involved.
In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either ZOLOFT (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the ZOLOFT group compared to a 19% decrease relative to baseline for the placebo group (p<). There was a 23% increase in Tmax for desmethyldiazepam in the ZOLOFT group compared to a 20% decrease in the placebo group (p<). The clinical significance of these changes is unknown.